A new format of single chain tri-specific antibody with diminished molecular size efficiently induces ovarian tumor cell killing

Biotechnology Letters

Volumn 27, Issue 22, 2005, Pages 1821-1827

  Liu, Jing ^a   Zhao, Qi ^a   Zhao, Baofeng ^b   Cheng, Julong ^c   Wang, Xiangbin ^a   Song, Liping ^a   Zhong, Zhang ^a   Lin, Qing ^a   Huang, Hualiang ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b LANZHOU UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Human CD3; Immunotherapy; Ovarian cancer; Single chain tri specific antibody; Variable region of heavy chain

Indexed keywords

BLOOD; CELL CULTURE; CELLS; CYTOLOGY; IMMUNOLOGY; TUMORS;

HUMAN CD3; IMMUNOTHERAPY; OVARIAN CANCER; SINGLE-CHAIN TRI SPECIFIC ANTIBODY; VARIBLE REGION OF HEAVY CHAIN;

ANTIBODIES;

IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; CHEMISTRY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MOLECULAR WEIGHT; OVARY TUMOR; PATHOLOGY; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR WEIGHT; OVARIAN NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 28344445823     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-005-6732-4     Document Type: Article

References (20)

1. N Bortoletto E Scotet Y Myamoto U D'Oro A Lanzavecchia 2002 Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells Eur. J. Immunol. 32 3102 3107
2. JL Cheng XB Wang Z Zhang HL Huang 2002 Construction and expression of a reshaped VH domain against human CD28 molecules Prep. Biochem. Biotechnol. 32 239 251
3. B Cochlovius SM Kipriyanov MJ Stassar J Schuhmacher A Benner G Moldenhauer M Little 2000 Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation Cancer Res. 60 4336 4341
4. D Colcher G Pavlinkova G Beresford BJ Booth A Choudhury SK Batra 1998 Pharmacokinetics and biodistribution of genetically-engineered antibodies Q. J. Nucl. Med. 42 225 241
5. V Cortez-Retamozo N Backmann PD Senter U Wernery P De Baetselier S Muyldermans H Revets 2004 Efficient cancer therapy with a nanobody-based conjugate Cancer Res. 64 2853 2857
6. M Fang R Zhao Z Yang Z Zhang H Li XT Zhang Q Lin HL Huang 2004 Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker Gynecol. Oncol. 92 135 146
7. SD Gillies Y Lan KM Lo M Super J Wesolowski 1999 Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors Cancer Res. 59 2159 2166
8. SJ Gong CJ Jin SY Rha HC Chung 2004 Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines Cancer Lett. 214 215 224
9. A Jemal T Murray A Samuels A Ghafoor E Ward MJ Thun 2003 Cancer statistics CA. Cancer J. Clin. 53 5 26
10. SM Kipriyanov G Moldenhauer J Schuhmacher B Cochlovius CW Von der Lieth ER Matys M Little 1999 Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics J. Mol. Biol. 293 41 56
11. A Lanzavecchia G Lezzi A Viola 1999 From TCR engagement to T cell activation: a kinetic view of T cell behavior Cell 96 1 4
12. O Manzke H Tesch J Lorenzen V Diehl H Bohlen 2001 Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation II Assessment of cellular immune responses Int. J. Cancer 91 516 522
13. RF Ozols 2002 Recurrent ovarian cancer: evidence-based treatment J. Clin. Oncol. 20 1161 1163
14. LP Song JL Cheng XB Wang Z Zhang M Fang ZY Zhou HL Huang 2003 A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells Acta Biochim. Biophys. Sin. 35 503 510 Shanghai
15. XB Wang BF Zhao Q Zhao JH Piao J Liu Q Lin HL Huang 2004 A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently J. Biochem. 135 555 565 Tokyo
16. S Weber A Traunecker F Oliveri W Gerhard K Karjalainen 1992 Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor Nature 356 793 796
17. X Xu P Clarke G Szalai JE Shively LE Williams Y Shyr E Shi FJ Primus 2000 Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein Cancer Res. 60 4475 4484
18. P Yeh D Landais M Lemaitre I Maury JY Crenne J Becquart A Murry-Brelier F Boucher G Montay R Fleer P Hirel J Mayaux D Klatzmann 1992 Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate Proc. Natl. Acad. Sci. USA 89 1904 1908
19. T Yokota DE Milenic M Whitlow J Schlom 1992 Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res. 52 3402 3408
20. Z Zhang ZH Li F Wang M Fang CC Yin ZY Zhou Q Lin HL Huang 2002 Overexpression of DsbC and DsbG markedly improves soluble and functional expression of single-chain Fv antibodies in Escherichia coli Protein Expr. Purif. 26 218 228